Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press63910.36691/RJA639ArticlesСтатьиResearch ArticleTHERAPEUTIC EFFICACY OF A POLY-FUNCTIONAL ANTIALLERGIC DRUG - RUPATADINEЛЕЧЕБНАЯ ЭФФЕКТИВНОСТЬ ПОЛИФУНКЦИОНАЛЬНОГО ПРОТИВОАЛЛЕРГИЧЕСКОГО ПРЕПАРАТА - РУПАТАДИНАGushchinI SГущинИгорь Сергеевичigushchin@yandex.ruInstitute of ImmunologyФГБУ «ГНЦ Институт иммунологии» ФМБА России15022013101NO1 (2013)№1 (2013)637710032020Copyright ©; 2013, Pharmarus Print MediaCopyright ©; 2013, Фармарус Принт Медиа2013Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/639

Rupatadine is a new poly-functional agent (selective histamine H 1-receptor and PAF-receptor antagonist with additional anti-inflammatory potency) for the management of patients with allergic rhinitis and chronic urticaria. It has a rapid onset of action, and its long-lasting effect permits once-daily dosing. It has been shown that rupatadine is effective, well-tolerated and safe in relieving symptoms in patients with seasonal and perennial/ intermittent and persistent allergic rhinitis and chronic urticaria.

Рупатадин — новое полифункциональное лекарственное средство (избирательный антагонист гистаминовых Н 1-рецепторов и PAF-рецепторов с дополнительной противовоспалительной активностью) для лечения аллергического ринита и хронической крапивницы. Рупатадин обладает быстро наступающим действием, а его продолжительный эффект позволяет использовать препарат один раз в сутки. Установлено, что использование рупатадина является эффективным, хорошо переносимым и безопасным методом лечения сезонного и круглогодичного/интермиттирующего и персистирующего аллергического ринита и хронической идиопатической крапивницы.

IgE-mediated allergyH -receptor antagonistsPAF-receptor antagonistsallergic rhinitischronic urticariarupatadineIgE-опосредованная аллергияантагонисты Н -рецепторовантагонисты PAF-рецептороваллергический ринитхроническая крапивницарупатадинАдо А.Д. Общая аллергология. М., «Медицина». 1978, 463 с.Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.Ferstl R., Akdis C.A., O’Mahony L. Histamine regulation of innate and adaptive immunity. Front. Biosci. 2012, v. 17, p. 40-53.Гущин И.С. Полифункциональная противоаллергическая активность антигистаминного препарата рупатадина. Рос. Аллергол. Журн. 2012, № 4, с. 3-12.Curtin M.L. Current status of platelet-activating factor antagonists. Exp. Opin. Ther. Patents. 1998, v. 8, p. 703-711.Mullol J., Bousquet J., Bachert C. et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008, v. 63 (Suppl. 87), p. 5-28.Bousquet J., van Couwenberg P., Khaltaev N. and WHO Panel. Allergic rhinitis and its impact on asthma. ARIA. In collaboration with the World Health Organization. J. Allergy Clin. Immunol. 2001, v. 108, p. S1-S315.Ciprandi G., Cirillo I., Vizzacaro A. et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life. Allergy. 2005, v. 60, p. 882-887.Demoly P., Allaert F.A., Lecasable M. et al. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003, v. 58, p. 672-675.Данилычева И.В. Крапивница. В кн.: Аллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, с. 461-472.Zuberbier T., Bindslev-Jensen C., Canonica W. et al. EAACI/ GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006, v. 61, p. 316-320.Katiyar S., Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Primary Care Respiratory Journal. 2009, v. 18, p. 57-68.Isquierdo I., Merlos M., Garcia-Rafanell J. Rupatadine, a new selective histamine H1-receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today. 2003, v. 39, p. 451-468.Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin. Pharmacother. 2006, v. 7, p. 1089-2001.Keam S.J., Plosker G.L. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007, v. 67, p. 457-474.Mion O., Campos R.A., Antilla M. et al. Futura study — Evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz. J. Otorhinolaryngol. 2009, v. 75, p. 673-679.Ciprandi G., Cirillo I. Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study. J. Biol. Regul. Homeostat. Agents. 2010, v. 24, p. 177-183.Valero A., Isquierdo I., Giralt J. et al. Rupatadine improves nasal symptoms, quality of life (ESPRINT-15) and severity in subanalysis of cohort of spanish allergy rhinitis patients. J. Investig. Allergol. Clin. Immunol. 2011, v. 21, p. 229-235.De Pita O., Giani M., Frezzolini A. et al. Rupatadine in treatment of chronic urticaria. Allergy. 2011, v. 66 (Suppl. 94), p. 273.Izquierdo I., Cranswick N., McCreanor J. et al. Rupatadine in children aged 6-11 years with allergic rhinitis: a proof of concept evaluation by a 4 weeks treatment follow-up study. Rupatadine oral solution, in children age 6-11 years with allergic rhinitis: a proof of concept evaluation and 4 weeks treatment follow-up efficacy and safety study. J. Compilation. 2009, v. 20 (Suppl. 20), p. 2.Saint-Martin F., Dumur J.P., Perez I. et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Invest. Allergol. Clin. Immunol. 2004, v. 14, p. 34-40.Potter P., Maspero J., Vermeulen J. et al. Rupatadine improves nasal symptoms control at 4 and 6 weeks in children with persistent allergic rhinitis. Allergy. 2011, v. 66 (Suppl. 94), p. 11.Stuebner P., Horak F., Zieglmayer R. et al. Effects of rupatadine vs placebo on allergen induced symptoms in patients exposed to aeroallergens in Vienna Challenge Chamber. Ann. Allergy Asthma Immunol. 2006, v. 96, p. 37-44.Valero F., Serrano C., Bartra J. et al. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. J. Investig. Allergol. Clin. Immunol. 2009, v. 19, p. 488-493.Izquierdo I., Paredes I., Lurigardos C. et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2000, v. 55 (Suppl. 63), p. 275.Perez I., De la Cruz G., Villa M., Izquierdo I. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy. 2002, v. 57 (Suppl. 73), p. 245.Izquierdo I., Paredes I., Lurigados C. et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2011, v. 66 (Suppl. 94), p. 275.Martinez-Cocera C., De Molina M., Marti-Guadano E. et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomized, double-blind parallel study. J. Invest. Allergol. Clin. Immunol. 2005, v. 15, p. 22-29.Guadano E.M., Serra-Batlles J., Meseguer J. et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis. Allergy. 2004, v. 59, p. 766-771.Maiti R., Rahman J., Jaida J. et al. Rupatadine and levocetirizine for seasonal allergic rhinitis. A comparative study of efficacy and safety. Arch. Otolaryngol. Head Neck Surg. 2010, v. 136, p. 796-800.Kowalski M., Jurkewitcz D., Kruszewski J. et al. Rupatadine 10 and 20 mg are effective in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo. Therapy. 2009, v. 6, p. 417-425.Molina M., Pinto E., Cistero A. et al. Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis. Therapy. 2010, v. 7, p. 429-436.Marmouz F., Giralt J., Izquierdo I. et al. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double blind, placebo-controlled trial. J. Asthma Allergy. 2011, v. 4, p. 27-35.Fantin S., Maspero J., Bisbal C. et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008, v. 63, p. 924-931.Potter P., Maspero J., Vermeulen J. et al. Rupatadine improves nasal symptoms control at 4 and 6 weeks in children with persistent allergic rhinitis. Allergy. 2011, v. 66 (Suppl. 94), p. 11-12.Gimenez-Arnau A., Pujol R.M., Ianosi S. et al. Rupatadine in the treatment of chronic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. 2007, v. 62, p. 539-546.Dubertret L., Zalupca L., Cristodoulo T. et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Eur. J. Dermatol. 2007, v. 17, p. 223-228.Gimenez-Arnau A., Perez I., Donado E. et al. Fast onset of action of rupatadine in the reduction of pruritus in patients suffering from chronic urticaria: pooled analysis. Allergy. 2007, v. 62 (Suppl. 83), p. 306.Gimenez-Arnau A., Izquierdo I., Mauer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J. Eur. Acad. Dermatol. Venerol. 2009, v. 23, p. 1088-1091.Metz M., Scholz E., Ferran M. et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann. Allergy Asthma Immunol. 2010, v. 104, p. 86-92.Karppinen A., Brummer-Korvenkontio H., Reunala T., Izquierdo I. Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy. J. Eur. Acad. Dermatol. Venerol. 2012, v. 26, p. 919-922.Valero A., de la Torre F., Castillo J.A. et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis. Drug Safety. 2009, v. 32, p. 33-42.Solans A., Li Carbo M., Pena J. et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin. Therapeutics. 2007, v. 29, p. 900-908.Гущин И.С. Кардиотоксическое действие антагонистов Н1-гистаминовых рецепторов. Клинич. фармакол. и терапия. 1998, № 3, с. 82-86.Ramis I., Giral M., Nieto C. et al. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac level. Allergy. 2000, v. 55 (Suppl. 63), p. 264.Giral M., Merlos M., Balsa D. et al. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines. Allergy. 1997, v. 52 (Suppl. 37), p. 44-45.Izquierdo I., Perez I., Villa M. et al. Lack of electrocardiographic effects of rupatadine, new nonsedating selective histamine H1-receptor and PAF antagonist. Allergy. 2001, v. 56 (Suppl. 68), p. 212.Caballero R., Valenzuela C., Longobardo M. et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1. 5 Br. J. Pharmacol. 1999, v. 128, p. 1071-1081.Donado E., Izquierdo I., Perez I. et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a «thorough QT/QTc study» performed according to ICH guidelines. Br. J. Clin. Pharmacol. 2010, v. 69, p. 401-410.Carvajal A., Macias D., Salado I. et al. Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese Pharmacovigilance System. Clin. Pharmacol. Therap. 2009, v. 85, p. 481-484.Nombela-Franco L., Ruiz-Antoran B., Toquero-Ramos J., Silva-Melchor L. Torsado de pointes associated with rupatadine. Rev. Esp. Cardiol. 2008, v. 61, p. 328-329.Fite R., Borja J. Rupatadine and heart rhythm disturbances. Clin. Pharmacol. Therap. 2010, v. 87, p. 37.Barbanoj M.J., Garcia-Gea C., Morte A. et al. Central and peripheral evaluation of rupatadine, a new antihistamine/ platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004, v. 50, p. 311-321.Barbanoj M.J., Garcia-Gea C., Antoniajoan R. et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum. Psychopharmacol. Clin. Exp. 2006, v. 21, p. 13-26.Garcia-Gea C., Ballester M.R., Martinez J. et al. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Brit. J. Clin. Pharmacol. 2010, v. 69, p. 663-674.Vuurman E., Theunissen E., van Oers A. et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum. Psychopharmacol.